JP2017512194A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512194A5
JP2017512194A5 JP2016553329A JP2016553329A JP2017512194A5 JP 2017512194 A5 JP2017512194 A5 JP 2017512194A5 JP 2016553329 A JP2016553329 A JP 2016553329A JP 2016553329 A JP2016553329 A JP 2016553329A JP 2017512194 A5 JP2017512194 A5 JP 2017512194A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
fgf
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016553329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512194A (ja
JP6431083B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053624 external-priority patent/WO2015124727A1/en
Publication of JP2017512194A publication Critical patent/JP2017512194A/ja
Publication of JP2017512194A5 publication Critical patent/JP2017512194A5/ja
Application granted granted Critical
Publication of JP6431083B2 publication Critical patent/JP6431083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016553329A 2014-02-20 2015-02-20 Fgf−18化合物の投与計画 Active JP6431083B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20
EP14000600.8 2014-02-20
PCT/EP2015/053624 WO2015124727A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (3)

Publication Number Publication Date
JP2017512194A JP2017512194A (ja) 2017-05-18
JP2017512194A5 true JP2017512194A5 (OSRAM) 2018-03-08
JP6431083B2 JP6431083B2 (ja) 2018-11-28

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016553284A Active JP6431082B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画
JP2016553329A Active JP6431083B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016553284A Active JP6431082B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Country Status (25)

Country Link
US (2) US9724388B2 (OSRAM)
EP (2) EP3119417B1 (OSRAM)
JP (2) JP6431082B2 (OSRAM)
KR (2) KR102410986B1 (OSRAM)
CN (2) CN106232622A (OSRAM)
AR (2) AR099510A1 (OSRAM)
AU (2) AU2015220773B2 (OSRAM)
BR (2) BR112016018696A2 (OSRAM)
CA (2) CA2938793A1 (OSRAM)
DK (2) DK3119417T3 (OSRAM)
ES (2) ES2688551T3 (OSRAM)
HR (2) HRP20181570T1 (OSRAM)
HU (1) HUE040350T2 (OSRAM)
IL (2) IL247084B (OSRAM)
LT (2) LT3119417T (OSRAM)
MX (2) MX2016010871A (OSRAM)
NZ (2) NZ723148A (OSRAM)
PL (2) PL3119417T3 (OSRAM)
PT (2) PT3107559T (OSRAM)
RS (2) RS57709B1 (OSRAM)
RU (2) RU2700582C2 (OSRAM)
SG (2) SG11201606505UA (OSRAM)
SI (2) SI3107559T1 (OSRAM)
WO (2) WO2015124727A1 (OSRAM)
ZA (2) ZA201605547B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10086112B2 (en) 2014-02-20 2018-10-02 Merck Patent Gmbh Implant comprising FGF-18
MX2016010871A (es) 2014-02-20 2016-11-17 Merck Patent Gmbh Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.
JP6787904B2 (ja) 2015-01-29 2020-11-18 アレス トレーディング ソシエテ アノニム 高度に正に荷電したタンパク質のイムノアッセイ
CN108697702A (zh) 2016-02-22 2018-10-23 诺华股份有限公司 使用fxr激动剂的方法
HUE058848T2 (hu) * 2017-09-29 2022-09-28 Merck Patent Gmbh FGF-18 vegyületre vonatkozó válaszkészség elõrejelzésére szolgáló gyulladásos biomarkerek
SI3687558T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Presnovni biooznačevalci za napovedovanje odzivnosti na spojino FGF-18
EP3850113B1 (en) 2018-09-10 2024-04-03 Merck Patent GmbH Markers useful in enrichment strategies for the treatment of osteoarthritis
US20220184180A1 (en) * 2019-02-08 2022-06-16 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551426B1 (en) * 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
US20060009389A1 (en) * 2004-07-06 2006-01-12 Moore Emma E Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
AR062522A1 (es) 2006-08-25 2008-11-12 Ares Trading Sa Tratamiento de desordenes en cartilagos
MY148277A (en) * 2006-08-25 2013-03-29 Ares Trading Sa Treatment of cartilage disorders with fgf-18
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
WO2012127506A1 (en) * 2011-03-22 2012-09-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
CN106232153B (zh) 2014-02-20 2020-01-17 默克专利有限公司 用于移植和组织工程手术的fgf-18
US10086112B2 (en) 2014-02-20 2018-10-02 Merck Patent Gmbh Implant comprising FGF-18
MX2016010871A (es) 2014-02-20 2016-11-17 Merck Patent Gmbh Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.

Similar Documents

Publication Publication Date Title
JP2017512194A5 (OSRAM)
JP2017507142A5 (OSRAM)
JP2012193216A5 (OSRAM)
JP2015517488A5 (OSRAM)
JP2015038135A5 (OSRAM)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2013231087A5 (OSRAM)
JP2015057451A5 (OSRAM)
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
FI3562486T3 (fi) Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
JP2016530280A5 (OSRAM)
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
RU2016137289A (ru) Схема применения соединения fgf-18
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2013541583A5 (OSRAM)
JP2017503014A5 (OSRAM)
JP2017501140A5 (OSRAM)
EP4410295A3 (en) Use of vibegron to treat overactive bladder
JP2016505050A5 (OSRAM)
JP2016512247A5 (OSRAM)
JP2018506533A5 (OSRAM)
JP2021505669A5 (OSRAM)
JP2017061488A5 (OSRAM)